Please login to the form below

Not currently logged in
Email:
Password:

Merck halts work on pain drug

Merck & Co and Canadian-headquartered Neuromed Pharmaceuticals have stopped the development of an experimental pain drug that disappointed in clinical trials

US-based Merck & Co and Canadian-headquartered Neuromed Pharmaceuticals have stopped the development of an experimental pain drug that disappointed in clinical trials.

Neuromed said in press statement: "NMED-160 (MK-6721) did not demonstrate the ideal pharmaceutical characteristics considered necessary to advance the compound further in development."

The drug is an N-type calcium channel blocker which was designed to interfere with the transmission of pain signals. Neuromed added that itself and Merck are still trying to develop similar products.

Merck entered into the agreement with Neuromed in March 2006, which was initially worth USD 475m to the company. Since Merckís Vioxx was withdrawn from the world market, Merck has been trying to find painkillers to fill its pipeline gap for this indication.

9th August 2007

Share

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Wisepress

Wisepress is a medical bookseller promoting and selling books worldwide, both online and via the 200 European medical conferences that...

Latest intelligence

WHITE PAPER: Why do men die younger?
It’s a commonly accepted fact that women outlive men. Wherever you live, there’s a good chance that men will die on average eight years earlier than women. Is this an...
3 tips to show patient diversity in your clinical trial materials
Here are some useful tips to help get your hands on authentically diverse stock photos....
01 PME-APR21 Cover.jpg
Virtual congresses: video thrilled the cardio tsar
Chris Ross explores the key learnings from a year of virtual congresses...

Infographics